UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of: August 2024
Commission File Number: 001-39152
| FSD PHARMA INC. |
| (Translation of registrant's name into English) |
199 Bay St., Suite 4000
Toronto, Ontario M5L 1A9, Canada
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
EXPLANATORY NOTE
On August 9, 2024, FSD Pharma, Inc. (the “Company”) issued a press release (“Press Release”) announcing a share consolidation, name change and other matters , which are described in more detail in Exhibit 99.1 attached hereto and incorporated herein by reference. The Press Release is incorporated by reference into the Company’s Registration Statement on Form F-3, (File No. 333-276264), as amended or supplemented, to the extent not superseded by documents or reports subsequently filed or amended.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
| FSD Pharma Inc. (Registrant) |
| |
|
|
|
|
|
| Date: August 9, 2024 | By: | /s/ Nathan Coyle |
|
|
|
| Nathan Coyle, Chief Financial Officer |
|
| 2 |
| Exhibit |
| Description |
|
|
|
|
|
| Press Release dated August 9 2024 – FSD Pharma Inc. Announces Share Consolidation and Name Change |
| 3 |